Patented technology that transforms key inflammatory messengers from agents of destruction to agents of repair
Designed to alter patients’
disease progression
Integrates seamlessly into existing hemodialysis delivery systems
Critically ill patients in the ICU often face an alarming, urgent situation. A dangerous, dysregulated hyperinflammatory response to infection, trauma or surgery can lead to multiorgan failure and in severe cases, even death. Today, there are no other FDA-approved therapeutic options to calm destructive hyperinflammation and restore balance in these critically ill patients.
SeaStar Medical is an innovator with groundbreaking solutions that are designed to stop this serious threat before it can do irreparable harm to these critically ill patients.
Backed by robust scientific evidence, our patented Selective Cytopheretic Device (SCD) is designed to neutralize the hyperinflammatory response to improve outcomes and save precious lives.
Our patented SCD therapy selectively targets the most highly activated neutrophils and monocytes responsible for destructive immune responses. The SCD technology not only stops the cytokine storm but may also reverse the damage of destructive hyperinflammation.
A shorter treatment regimen to reach the desired effect may reduce dependency on dialysis and time in the ICU. This can help put patients on the road back to recovery sooner and free up resources more quickly.
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. Our first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA-approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic-like condition in critically ill pediatric patients. Our Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. We are currently conducting a pivotal trial of our SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
©SeaStar Medical 2023